Use of Bosentan, Theophylline and Vardenafil in Treatment of Priapism

Priapizm Tedavisinde Bosentan, Teofilin ve Vardenafil Kullanımı

Ihsan Unus¹, Ahmet Karakeci², Tunc Ozan², Fatih Firdolas², Irfan Orhan²

ÖZET

Amaç: Endotelin reseptör blokeri olan Bosentan, Adenosin reseptör blokeri olan Teofilin ve non selektif Fosfodiesterase 5 enzimi inhibitörü olan Vardenafil a non-iskevik Priapizm oluşturmuş rat modelinde terapötik etkinliğinin araştırılması hedeflendi.

Yöntemler: Randomize olarak 24 Sprague-Dawley rat kontrol grubu, Vardenafil grubu, Bosentan grubu ve Teofilin grubu olmak üzere 4 eşit gruba dağıtıldı. Ereksiyon her grupta vakum konstriksiyon metodu ile sağlandı ve priapizm sağlanması için 4 saat sürdüldü. Daha sonra her gruptaki 6 rata Servikal dislokasyon yöntemi ile dekapitasyon uygulandı. Kavernöz dokular ayrıldı ve organ banyosuna bırakıldı. Doku örnekleri 0,5-0,2 cm. şeritler şeklinde ısı çeperli, çift duvarlı içinde 37°C krebs çözeltisi bulunan ve devamlı 95% O2 ve 5% CO2 ile gazlandırılan organ banyolarına istirahat gerimi 1000 mg. olacak şekilde asırdılar. Kontrol grubu dışında kalan grupların 1 saatlik kasılma kayıtları alındıktan sonra grupuna göre artan dozlarda Bosentan, Teofilin ve Vardenafil uygulandı ve şeritlerdeki ilaç ve doz bağımlı kontraksiyon değişiklikleri gözlandı.

Bulgular: Bu çalışmada Bosentanın priapizm oluşturulmuş Kavernöz doku kasılmalarında frekans ve amplitüdleri istatistiksel olarak anlamlı şekilde arttırdı, Theophylline, Vardenafılı ise frekans ve amplitüdüde herhangi bir etki gözlenmedi.

Sonuç: Priapizm ile induklenmiş apoptozisin Bosentan ile inhibe edilmesi erektil fonksiyonun korunması açısından umut vaat etmektedir.

Anahtar kelimeler: Bosentan, iskemik priapizm, teofilin, vardenafil

ABSTRACT

Objective: To evaluate the early therapeutic alternatives such as Bosentan an Endothelin receptor blocker, Theophylline and Adenosin receptor blocker and Vardenafil a non-selective Phosphodiesterase 5 enzyme inhibitor for the therapy of ischemic priapism in the rat models.

Methods: Twenty-four Sprague-Dawley rats were randomly divided into 4 equal groups. Control group, Vardenafil group, Bosentan group and Theophylline group. Erection was provided by vacuum constriction method and it was maintained for 4 hours for achieving the priapism in all groups. Then, Six rats from each group were sacrificed by cervical dislocation. Consequently, cavernous tissue samples were collected and placed in the tissue bath. Tissue samples were prepared as 0.5-0.2 cm. strips and put into heat jacketed double walled organ bath containing 37°C krebs solution which is constantly bubbled with 95% O2 and 5% CO2 and mounted at a resting tension of 1000 mg. After taking the 1 hour record of the three groups except the control group, Bosentan, Theophylline and Vardenafil were admitted in increasing doses. Consequently the alterations of the contractions in the strips due to the drugs and their increasing doses are observed.

Results: In this study we detected that Bosentan increased the frequency and amplitude of the contractions of the cavernous tissue in the Priapism status in a statistically significant manner, Theophylline decreased the frequency and the amplitude significantly and Vardenafil had statistically no effect on the frequency and amplitude.

Conclusion: Inhibition of priapism induced apoptosis with Bosentan, seems promising on preserving erectile function.

Key words: Bosentan, ischemic priapism, theophylline, vardenafil
INTRODUCTION

Priapism is a full or partial erection that continues more than 4 hours beyond sexual stimulation and orgasm or is unrelated to sexual stimulation. There are three kinds of priapism: ischemic priapism (veno-occlusive, low flow), stuttering priapism (intermittent), and non-ischemic priapism (arterial, high flow) [1]. Typically, only the corpora cavernosa are affected [2].

Ischemic priapism (veno-occlusive, low flow) is a persistent erection marked by rigidity of the corpora cavernosa, and little or no cavernous arterial inflow. In ischemic priapism, there are time-dependent changes in the corporal metabolic environment with progressive hypoxia, hypercarbia, and acidosis. The patient typically complains of penile pain and the examination reveals a rigid erection. The condition is analogous to a muscle compartment syndrome, with well-documented histological changes occurring to the corporal smooth muscle by 12 hours. Interventions beyond 48-72 hours of onset may help relieve erection and pain, but have little benefit in preserving potency. Histologically, by 12 hours, corporal specimens show interstitial edema, progressing to destruction of sinusoidal endothelium, exposure of the basement membrane, and thrombocyte adherence at 24 hours. At 48 hours, thrombi can be found in the sinusoidal spaces and smooth muscle necrosis with fibroblast-like cell transformation is evident [3].

The tone of arterial and cavernous smooth muscle cells is a key regulator of tumescence and detumescence, and is determined by the balance of relaxants and constrictors [3]. Compared to normal erection, the turning point for ischemic priapism is the disruption of the smooth muscle cells (SMC) tone control system, which is induced by obviously cause-effect pharmaceutical agents, inexplicit Sickle Cell Disease (SCD), and other hematological dyscrasias, and obscure causes [4].

Ischemic priapism (including stuttering priapism) thus becomes the research focus, because it is more common and associated with poorer outcomes as compared with non ischemic priapism [5]. The causes of ischemic priapism include hematologic dyscrasias and medication used in treatment of erectile dysfunction (ED) and psychosis treatment, although over 46% of the cases are elusive [4, 6]. In addition, mediators such as adenosine, noradrenaline, endothelin and rho-kinase also play major roles in the regulation of penile smooth muscle tone. Recently, it was shown in experimental priapism models that adenosine and endothelin are effective in the development of recurrent priapism attacks. Moreover, it was reported that dysregulated phosphodiesterase type 5 (PDE-5) activity, decreased NE response and altered endothelin receptor activity may be effective in the pathophysiology of priapism.

Two aims were described for this experimental ischemic priapism study. First the effect of Endothelin-1 (ET-1), Adenosine Deaminase (ADA), PDE-5 enzymes on the cavernosal smooth muscle tissue were assessed. Secondly; the possible preventive effect of Endothelin receptor blockers (Bosentan), Adenosine receptor blockers, non selective phosphodiesterase inhibitors (Theophylline) and verdafenil a PDE-5 inhibitor on the observed cavernosal smooth muscle in ischemic priapism.

METHODS

This study was approved by Ethical Committee of Experimental Research on Animals. Twenty-four adult, Sprague Dawley male rats with a mean weight of 245-300 gr were used. They were divided into four equal groups; all were housed under constant environmental conditions and were fed on standard laboratory rat chow and distilled water. The rats were randomly divided into 4 groups, each containing 6 rats: the control group, Vardenafil group, Bosentan group, Theophylline group. Erection was provided by vacuum constriction method and it was maintained for 4 hours for achieving the priapism in all groups. Then, six rats from each group were sacrificed by cervical dislocation.

In organ bath experiments the paired corpora cavernosa had the tunica albuginea removed, were divided into a total of 10-14 strips, 2-5 mm in length, and tied between thin threads. Cavernous tissue samples were collected and placed in the tissue bath. The reparations were suspended in 10 ml organ baths containing Krebs solution at 20°C, and after 20 min were heated to 37°C during continuous aeration with 5% CO₂ in O₂ and are mounted at a resting tension of 1000 mg. The muscle prepa-
rations received trans-mural electrical field stimulation (EFS). Mechanical muscular activity was recorded isometrically by Grass force-displacement transducers (FT03; Grass Products, Warwick, USA). After taking the 1 hour record of the three groups except the control group. Vardenafil (Levitra; Bayer, Istanbul, Turkey), Bosentan (Bosentan; Sigmaaldrich, St. Louis, USA); and Theophylline (Aminocardol; Novartis, Istanbul, Turkey) were admitted in increasing doses (10 µmol, 100 µmol ve 1000 µmol). Bosentan and vardenafil were dissolved in distilled water and Theophylline were dissolved in dimethyl sulfoxide. Consequently the alterations of the contractions in the stripped due to the drugs and their increasing doses are observed.

Experimental data are expressed as mean ± s.e.m. All statistical calculations were done by using a computer program (Statistical Package for Social Sciences 21.0). Mann-Whitney U test was used for comparison with the control group. Significant difference between treatment groups was accepted for \( p<0.05 \).

**RESULTS**

In this study we detected that Theophylline decreased the frequency and amplitude of the contractions of the cavernous tissue in the priapism status in a statistically significant manner compared to control group. Furthermore, application of Theophylline with increasing doses (10 µmol, 100 µmol ve 1000 µmol) lowered the tone of the tissue (Table 1).

| Table 1. Effect of Theophylline administration to the frequency and amplitude of the contractions (mean ± s.e.m). |
| --- |
| Control (n=6) | 10 µM (n=6) | 100 µM (n=6) | 1000 µM (n=6) |
| Frequency | 100.0±0.0 | 69.1±18.0** | 40.4±29.7** | 14.3±12.1** |
| Amplitude | 100.0±0.0 | 77.7±16.9** | 44.3±13.8** | 19.5±10.8** |

\*: \( p<0.05 \); **: \( p<0.01 \)

Vardenafil has statistically no effect on the frequency and amplitude in the priapic ischemic cavernous tissue compared to control group (Table 3).

| Table 3. Effect of Vardenafil administration to the frequency and amplitude of the contractions (mean ± s.e.m). |
| --- |
| Control (n=6) | 10 µM (n=6) | 100 µM (n=6) | 1000 µM (n=6) |
| Frequency | 100.0±0.0 | 94.2±11.5* | 92.4±19.7* | 103.3±21.3* |
| Amplitude | 100.0±0.0 | 97.7±16.8* | 96.5±15.3* | 93.1±16.5* |

*: \( p>0.05 \)

**DISCUSSION**

In recent years, many studies that have been made on the physiology of penile erection and pathophysiology of erectile dysfunction revealed the cavernosal smooth muscle tone regulation mechanisms. Especially in the treatment of ischemic priapism, using the mediators that active on the regulation of penile cavernosal smooth muscle is the new research topics.

Adenosine signaling plays important roles in regulating homeostasis in a number of physiological systems including the cardiovascular, nervous, renal, immune systems and erectile function. Adenosine is a signaling nucleoside that elicits its effect on target cells by engaging specific G-protein-coupled receptors [7]. Four such receptors have been described: A1 adenosine receptor (A1R), A2A adenosine receptor (A2AR), A2B adenosine receptor (A2BR), and A3 adenosine receptor (A3R). Each receptor has a unique affinity for adenosine and a distinct cellular and tissue distribution. Most evidence suggests that the A1 and A3 adenosine receptors are coupled to adenylyl cyclase by the inhibitory G-protein subunit (Goi) and hence serve to lower intracellular levels of the second messenger cyclic adenosine monophosphate (cAMP) [8,11]. The A2A and A2B adenosine receptors are commonly coupled to adenylyl cyclase by the stimula-
Adenosine shares multiple features with nitric oxide (NO), making it an excellent candidate for contributing to normal and abnormal penile erection. Adenosine-mediated cAMP induction and NO-mediated cyclic guanosine monophosphate (cGMP) induction are capable of activating protein kinase A and protein kinase G, respectively, resulting in decreased calcium calmodulin-dependent myosin light chain phosphorylation and enhanced smooth muscle relaxation [13]. Dai et al. [14]. Reported that the increasing amount of Adenosine in the cavernosal tissue is prolonging the erection through A2B receptor. Also in the same study it is reported that the erection is terminated with the polyethylene glycol-modified (PEG-ADA) therapy which is the modified form of the enzyme ADA This effect occurs in the cavernous tissues, destruction of adenosine by the deaminase enzyme. These experimental data suggest that increased levels of adenosine in the cavernosal tissue, may be effective in priapism. In pathogenesis of priapism, adenosine is likely to be effective via A2B receptor. There is no study about blocked A2B receptors and the result of this condition.

In our study, the non-selective adenosine receptor antagonist theophylline was used. As well as, nonselective adenosine receptor blocker theophylline, is thought to act through mechanisms such as PDE inhibition, stimulation of catecholamine secretion, inhibition of mediators (prostaglandins, TNF-alpha), intracellular calcium release, inhibition of histone deacetylase activity increased (increasing the effectiveness of corticosteroids effect). Chiang et al. [15]. reported that, Theophylline, an adenosine receptor antagonist, inhibited adenosine-induced penile tumescence. Tiejuan et al. [16]. reported that treatment with theophylline significantly inhibited adenosine-mediated corpora cavernosal strips (CCS) relaxation in a dose-dependent manner. We observed that theophylline decreased the frequency and amplitude of the contractions of the cavernous tissue in the priapism status in a statistically significant manner. And according to the control group at concentration of 10 µM, 100 µM, 1000 µM theophylline increased smooth muscle relaxation in a statistically significant manner.

ET-1 is expressed by endothelial and stromal cells of the human penis since the earliest stages of external genitalia development [17]. And is considered the most potent stimulator of trabecular SMC [18].

In normal organ systems ET1 constitute the vasoconstrictor effect via ETA receptors. However, under pathological conditions, such as hypoxia, ET-1 acting as a defense mechanism, reveals vasodilation via ETB receptor. Prolonged hypoxia in penile SMCs activated other counter-regulatory mechanisms, besides an up-regulation of ETB receptors. Endothelin plays an active role in the regulation of penile smooth muscle tone and cause dilation of the hypoxic corpus cavernosum smooth muscle [19]. Filippi et al observed that in preparations of human fetal smooth muscle cells, prolonged hypoxia (more than 24 h) dramatically increased ETB receptor expression and responsiveness, as well as ET-1 gene and protein expression. During hypoxia, contractile effect of ET-1 is mediated by increased NO production and/or activity in penile cells, most probably mediated by the decreased previously described ETB receptor up-regulation [19].

Bosentan, is a nonselective endothelin receptor blocker and possesses the effect of vasodilation and antiproliferation [20]. Karakeci et al. have reported that inhibition of priapism induced apoptosis with bosentan, preserving erectile function [21]. By utilizing the mentioned effects of Bosentan we aimed to decrease the rate of ETB receptors in the cavernosal smooth muscle cells of the ischemic cavernosal tissue. Our study results have shown that Bosentan increased the frequency and amplitude of the contractions of the cavernous tissue in the priapism status in a statistically significant manner by blocking endothelin B receptors.

PDE-5 inhibitors selectively on the erectile tissue causing penile smooth muscle relaxation and vasodilatation leading to penile erection. Bialecki et al. [22]. first reported on sildenafil having a paradoxical effect in controlling stuttering priapism in three patients with SCD. Although this proposal would immediately seem illogical based on the knowledge that PDE5 inhibitors exert erectogenic effects, scientific basis for using these agents to treat priapism. In a small case series, Burnett et al. [23]. Have shown that daily sildenafil or tadalafil
therapy reduces ischemic priapism episodes in men with stuttering priapism. Accordingly, when used in long-term dosing regimen unassociated with erection stimulatory conditions, PDE5 inhibitor therapy alleviates recurrent priapism episodes in men with SCD-associated priapism and idiopathic priapism without affecting normal erectile capacity [24,25]. The working theory is that surges of cGMP go unchecked because of downregulated levels of PDE5; this results in stimuli-like nocturnal erection resulting in unchecked corporal smooth muscle relaxation. PDE5 inhibitors should be started under conditions of complete penile flaccidity, not during a stuttering episode. Efficacy is seen after a week or more of dosing [26]. Addition, transgenic sickle mice, which also display a priapic phenotype [27,28] also has lowered PDE5 activity in the penis transfection of endothelial Nitric Oxide Sentase (eNOS) into the penis of eNOS knockout mice restored both the expression of phosphorylated PDE5 and erectile response to near normal levels [29]. Together, these data suggest that PDE5 dysregulation is a fundamental mechanism for priapism. Interestingly, it has been shown that chronic PDE5 inhibitor administration alleviated or resolved priapism recurrences in six of seven patients who have sickle cell disease-associated “stuttering” priapism or idiopathic recurrent priapism [23]. Chronic PDE5 inhibitor administration prevents recurrent priapism by reconditioning PDE5 regulatory function.

In our study, we used vardenafil which is phosphodiesterase type 5 inhibitors. We observed that Vardenafil had no effect in the priapic ischemic cavernous tissue. Therefore, acute administration of phosphodiesterase type 5 inhibitors can not resolve priapism, chronic PDE5 inhibitor administration can solve priapism.

The mechanism of nonischemic priapism is documented, along with its treatment; whereas the mechanism of ischemic priapism is still somewhat unclear [4]. Especially in the treatment of ischemic priapism, using the mediators that active on the regulation of penile cavernosal smooth muscle is the new research topics. In our study it is aimed to discover new therapy alternatives. In this study we detected that Bosentan increased the frequency and amplitude of the contractions of the cavernous tissue in the priapism status in a statistically. Bosentan promising on treating of ischemic priapism.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**REFERENCES**

1. Montague DK, Jarow J, Broderick GA, et al. American urological association guideline on the management of priapism. J Urol 2003;170:1318-1324.
2. Hinman F Priapism: Report of cases in a clinical study of the literature with reference to its pathogenesis and surgical treatments. Ann Surg 1914;60:689-716.
3. Burnett AL. Neophysiology of erectile function: Androgenic effects. J Androl. 2003;24:825.
4. Yuan J, DeSouza R, Westney OL, et al. Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl 2008;10:88-101.
5. Pautler SE, Brock GB. Priapism. Urol Clin North Am 2001;28:391-403.
6. Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, Kavoussi AR, et al, editors. Campbell’s Urology. Philadelphia: WB Saunders, 2002.1610-16967.
7. Fredholm BB, AP IJ, Jacobson KA, et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527-552.
8. Lad PM, Nielsen TB, Londos C, et al. Independent mechanisms of adenosine activation and inhibition of the turkey erythrocyte adenylyl cyclase system. J Biol Chem 1980;255:10841-10846.
9. Cooper DM, Londos C, Rodbell M. Adenosine receptor-mediated inhibition of rat cerebral cortical adenylyl cyclase by a GTP-dependent process. Mol Pharmacol 1980;18:598-601.
10. Londos C, Cooper DM, Wolff J. Subclasses of external adenosine receptors. Proc Natl Acad Sci USA 1980;77:2551-2554.
11. Palmer TM, Stiles GL. Identification of an A2a adenosine receptor domain specifically responsible for mediating short-term desensitization. Biochemistry 1997;36:832-838.
12. Stiles GL. Adenosine receptor subtypes: new insights from cloning and functional studies. In: Jacobson KA, Jarvis MF, editors. Purinergic approaches in experimental therapeutics. New York: Wiley-Liss Inc 1997:29-37.
13. Lin CS, Lin G, Lue TF. Cyclic nucleotide signaling in cavernous smooth muscle. J Sex Med 2005;2:478-491.
14. Yingbo Dai, Yujin Zhang, Phatarpekar MS, et al. Adenosine Signaling, Priapism and Novel Therapies. J Sex Med 2009;6:292-301.
15. Chiang PH, Wu SN, Tsai EM, et al. Adenosine modulation of neurotransmission in penile erection. Br J Clin Pharmacol 1994;38:357-362.

16. Mi T, Abbasi S, Zhang H, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 2008;118:1491-501.

17. Granchi S, Vannelli GB, Vignozzi L, et al. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. Mol Hum Reprod 2002;8:1053-64.

18. Andersson K.E. Pharmacology of penile erection. Pharmacol Rev 2001;53:417-50.

19. Filippi S, Marini M, Vannelli GB, et al. Effects of hypoxia on endothelin-1 sensitivity in the Corpus cavernosum. Mol Hum Reprod 2003;9:765-774.

20. Hall SM, Davie N, Klein N, et al. Endothelin receptor expression in IPAH: effect of bosentan and epoprostenol treatment. Eur Respir J 2011;38:851-860.

21. Karakeci A, Firdolas F, Ozan T, et al. Second pathways in the pathophysiology of ischemic priapism and treatment alternatives. Urology 2013;82:625-629.

22. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med 2002;113:252.

23. Burnett AL, Bivalacqua TJ, Champion HC, et al. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006;3:1077-84.

24. Bivalacqua TJ, Musicki B, Champion HC, Burnett AL. Phosphodiesterase type 5 inhibitor therapy for priapism. In: Carson CC III, Kirby RS, Goldstein I, Wyllie MG, eds. Textbook of erectile dysfunction. 2nd edn. New York: Informa Healthcare 2009:428-433.

25. Burnett AL, Bivalacqua TJ, Champion HC, et al. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 2006;67:1043-1048.

26. Broderick GA, Kadioglu A, Bivalacqua TJ, et al. Priapism: Pathogenesis, epidemiology, and management. J Sex Med 2010;7:476-500.

27. Beuzard Y. Transgenic mouse models of sickle cell disease. Curr Opin Hematol 1996;3:150-155.

28. Trudel M, De Paepe ME, Chrétien N, et al. Sickle cell disease of transgenic SAD mice. Blood 1994;84:3189-3197.

29. Champion HC, Bivalacqua TJ, Takimoto E, et al. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 2005;102:1661-1666.